Clinical trials: Stage III Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive…
- Trial name
- ARASENS (NCT02799602)
- Testing
- BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel
- Where
- 322 sites in United States, Australia and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Bayer
Prostatic Neoplasms, Castration-Resistant
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in combination with enzalutamide compared with enzalutamide…
- Trial name
- IMbassador250 (NCT03016312)
- Testing
- Atezolizumab, Enzalutamide
- Where
- 158 sites in United States, Australia and 19 more
- Volunteers
- 759 people
- Sponsor
- Hoffmann-La Roche
Oligometastatic Prostate Cancer (OMPC)
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary…
- Trial name
- PSMA-DC (NCT05939414)
- Testing
- AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
- Where
- 144 sites in United States, Argentina and 25 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
The purpose of this clinical research study is to assess the safety and efficacy of an investigational therapy called DCVax(TM)-Prostate.
- Trial name
- NCT00043212
- Testing
- Dendritic cell immunotherapy
- Where
- 16 sites in United States
- Sponsor
- Northwest Biotherapeutics
Prostate Cancer
Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061867
- Testing
- pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
- Where
- 2 sites in United States
- Sponsor
- Imunon
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
MCRPC
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating the efficacy and safety of HC-1119 soft capsules versus placebo in mCRPC patients who have failed or become intolerant to the…
- Trial name
- NCT03851640
- Testing
- HC-1119
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Metastatic Castration-resistant Prostate Cancer
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
The VIABLE study sought to confirm the hypothesis that the combination of docetaxel with DCVAC/PCa followed by a maintenance therapy with DCVAC/PCa would improve overall survival in patients with metastatic castration-resistant…
- Trial name
- VIABLE (NCT02111577)
- Testing
- DCVAC/PCa
- Where
- 177 sites in United States, Austria and 20 more
- Volunteers
- 1,182 people
- Sponsor
- SOTIO a.s.
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Prostate Cancer
Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer
In this study, 18F-Florastamin PET/CT will be performed in patients with at least intermediate risk prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
- Trial name
- NCT06011304
- Testing
- [18F]Florastamin Injection
- Where
- China
- Volunteers
- 287 people
- Sponsor
- HTA Co., Ltd.
Prostate Cancer
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
Enthuse M1 is a large phase III clinical trial studying the safety and efficacy of ZD4054 (Zibotentan) in patients with hormone resistant prostate cancer and bone metastases.
- Trial name
- ENTHUSE M1 (NCT00554229)
- Testing
- ZD4054
- Where
- 197 sites in United States, Argentina and 29 more
- Volunteers
- 896 people
- Sponsor
- AstraZeneca
Metastatic Prostate Cancer, Lung Cancer
Cannabis Oil and Radiation Therapy for the Management of Pain
In this innovative approach seeking effective therapeutic strategies, the investigators are proposing to test the effectiveness of medical cannabis oil as an adjunct to palliative Radiation Therapy (RT) and Best Supportive Care…
- Conditions
- Metastatic Prostate Cancer, Lung Cancer, Breast Cancer
- Trial name
- NCT03763851
- Testing
- Active PPP005, Radiotherapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Tetra Bio-Pharma
Prostate Cancer, Prostate Cancer Recurrent
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
This study evaluates the diagnostic performance and safety of [18F]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
- Trial name
- NCT04742361
- Testing
- [18F]PSMA-1007
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 136 people
- Sponsor
- ABX advanced biochemical compounds GmbH
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Prostatic Neoplasms, Breast Cancer
Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)
The primary objective is: To determine the efficacy of modafinil in the reduction of fatigue in patients with metastatic breast or prostate cancer undergoing docetaxel-based chemotherapy The secondary objectives are: To determine…
- Trial name
- NCT00917748
- Testing
- DOCETAXEL(XRP6976) + MODAFINIL, Modafinil
- Where
- Australia
- Volunteers
- 84 people
- Sponsor
- Sanofi
Metastatic Castration-Sensitive Prostate Cancer
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants…
- Trial name
- EvoPAR-PR01 (NCT06120491)
- Testing
- Saruparib, Abiraterone Acetate, Darolutamide
- Where
- 322 sites in United States, Australia and 22 more
- Volunteers
- 1,898 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic…
- Trial name
- PSMAfore (NCT04689828)
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Where
- 72 sites in United States, Austria and 12 more
- Volunteers
- 469 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the…
- Trial name
- NCT07365995
- Testing
- BNT324, Docetaxel, Prednisone/prednisolone
- Where
- 52 sites in United States, Australia and 5 more
- Volunteers
- 736 people
- Sponsor
- BioNTech SE